Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03724552 · ClinicalTrials.gov registry record · NA
Photobiomodulation in Autism Spectrum Disorder (ASD)
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03724552: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03724552 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03724552, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this 8-week open-label study is to assess the tolerability, safety, and efficacy of Transcranial LED Therapy in patients with Autism Spectrum Disorder (ASD). The investigators propose to enroll up to 30 subjects of both genders ages 9-59 years with intact intellectual functions who meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Autism Spectrum Disorder (ASD).
Interventions
- DEVICE Transcranial LED Therapy (Participants ages 9-17)
- DEVICE Transcranial LED Therapy (Participants ages 18-59)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-13 |
| Est. Completion | 2019-11-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03724552
The ClinicalTrials.gov registry entry for NCT03724552 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial LED Therapy (Participants ages 9-17) is the first listed.
NCT03724552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03724552 about?
NCT03724552 is a clinical study titled "Photobiomodulation in Autism Spectrum Disorder (ASD)". The purpose of this 8-week open-label study is to assess the tolerability, safety, and efficacy of Transcranial LED Therapy in patients with Autism Spectrum Disorder (ASD). The investigators propose to enroll up to 30 subjects of both genders ages 9-59 years with intact intellectual functions who me...
What is the current status of trial NCT03724552?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-04-13. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT03724552?
The interventions under investigation include: Transcranial LED Therapy (Participants ages 9-17) (DEVICE), Transcranial LED Therapy (Participants ages 18-59) (DEVICE).
Who is sponsoring clinical trial NCT03724552?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.